Showing results (41-50 of 136) with videos related to
Sort By:
Pageof 14
Cancer Research|June 29, 2023
Oncogenic ASPM Is a Regulatory Hub of Developmental and Stemness Signaling in CancersKelvin K Tsai, Byoung-Il Bae, Chung-Chi Hsu, et al.Cancer Research|August 9, 2003
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cellsFrancesco Bertolini, Saki Paul, Patrizia Mancuso, et al.Biomaterials|March 25, 2011
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignancesEhud Segal, Huaizhong Pan, Liat Benayoun, et al.Neoplasia (New York, N.Y.)|January 20, 2011
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamideUrban Emmenegger, Giulio Francia, Annabelle Chow, et al.Journal for Immunotherapy of Cancer|August 27, 2020
IL-31 induces antitumor immunity in breast carcinomaTal Kan, Erik Feldman, Michael Timaner, et al.Oncotarget|October 27, 2015
Host JDP2 expression in the bone marrow contributes to metastatic spreadYelena Barbarov, Michael Timaner, Dror Alishekevitz, et al.International Journal of Cancer|July 24, 2020
Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer-derived extracellular vesiclesTamar Barenholz-Cohen, Yulia Merkher, Jozafina Haj, et al.Molecular Pharmaceutics|May 7, 2011
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse modelKeren Miller, Anat Eldar-Boock, Dina Polyak, et al.Blood|July 7, 2005
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activityYuval Shaked, Urban Emmenegger, Shan Man, et al.Acta Oncologica (Stockholm, Sweden)|September 14, 2007
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patientsDavid Loven, Einat Be'ery, Rinat Yerushalmi, et al.Pageof 14